Daptomycin (Cubicin® Novartis Inc. Spain) was generously provided by the manufacturer. Teicoplanin (Targocid® Marion-Merrel S.A. Spain), clarithromycin (Klacid® Abbot Laboratories S.A.), and gentamicin (Normon S.A. Spain) were commercially purchased as drug powder (Teicoplanin and clarithromycin) or as 20 mg/mL IV solution (gentamicin). Ethanol was commercially purchased as 70 % dilution (Lab. Reig Jofré. S.A. Spain). Drug powders were reconstituted following the CLSI guidelines [34 ].
Susceptibility testing was performed using e-test methodology but for DAP that was performed by microdilution following CLSI guidelines [34 ]. Mueller Hinton broth supplemented with 50 μg/ml calcium, and 12.5 μg/ml magnesium (SMHB) was used for susceptibility testing involving DAP.
Tryptic Soy Broth supplemented with 1 % glucose (TSBg) was used for biofilm growth.
To evaluate drug stability, each solution was incubated over 72 h, and then evaluated for physical compatibility by particulate formation, colour change, or gas evolution [31 (link)–33 (link)]. All drug-combinations maintained their initial conditions and were considered stable.
Susceptibility testing was performed using e-test methodology but for DAP that was performed by microdilution following CLSI guidelines [34 ]. Mueller Hinton broth supplemented with 50 μg/ml calcium, and 12.5 μg/ml magnesium (SMHB) was used for susceptibility testing involving DAP.
Tryptic Soy Broth supplemented with 1 % glucose (TSBg) was used for biofilm growth.
To evaluate drug stability, each solution was incubated over 72 h, and then evaluated for physical compatibility by particulate formation, colour change, or gas evolution [31 (link)–33 (link)]. All drug-combinations maintained their initial conditions and were considered stable.